# Eyevensys

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/eyevensys

- Industry: Biotechnology
- Headquarters: Paris, France
- Website: www.eyevensys.com
- Total disclosed funding: $26M
- Latest round: Series B (Aug 4, 2021)
- Investors on record: 9

## About

Eyevensys SAS is a biotechnology company specializing in innovative non-viral vectorized therapies for severe retinal diseases, particularly focusing on age-related macular degeneration (AMD) and geographic atrophy (GA).Founded in 2008 in Paris, France, Eyevensys SAS develops therapies for retinal diseases. The company has successfully raised funding through multiple rounds, including its most recent Series B round in August 2021, where it secured EUR 10 million from investors such as Boehringer Ingelheim Venture and Korea Investment Partners. Eyevensys SAS has completed a total of 6 deals to date.Eyevensys SAS specializes in two key products: PST-611 and PST-809. PST-611 targets dry AMD and GA by utilizing a plasmid that expresses human transferrin, crucial for managing retinal iron levels and oxidative stress, while PST-809 is focused on wet AMD, combining anti-VEGF components with decorin to tackle both VEGF-dependent and independent pathways. These therapies cater to a global market where AMD affects over 200 million individuals, particularly in Europe, North America, and parts of Asia.Eyevensys SAS generates revenue primarily through partnerships with healthcare institutions and licensing agreements for its therapies, PST-611 and PST-809. These products are integrated into patient treatment regimens within ophthalmology, allowing for tailored service delivery and long-term solutions for vision loss caused by retinal diseases. Revenue is expected from these collaborations, facilitating the distribution and administration of the therapies.Eyevensys SAS plans to utilize the EUR 10 million raised in Series B funding to accelerate the development of its EYS809 program aimed at treating wet AMD. The company is targeting expansion into new markets, particularly in regions with high AMD prevalence, by leveraging partnerships with healthcare providers. The funding will support the ongoing development and potential launch of EYS809, further enhancing Eyevensys' presence in the ophthalmology sector.

## Funding rounds

- Series B, Aug 4, 2021, $10M — Karista, Boehringer Ingelheim Venture, Korea Investment Partners, Inserm Transfert Initiative, Bpifrance Investissement, Pureos Bioventures
- Series B, Jan 8, 2020, $11M — Karista, Pontifax Venture Capital, Boehringer Ingelheim Venture, Inserm Transfert Initiative, Bpifrance Investissement, GF Securities, GF Investments (Hong Kong), Pureos Bioventures
- Series A, Jun 15, 2016, $3.6M — Karista, Pontifax Venture Capital, Boehringer Ingelheim Venture, Inserm Transfert Initiative, Bpifrance Investissement
- Series A, Jul 29, 2015, $1.8M — Karista, Boehringer Ingelheim Venture, Inserm Transfert Initiative, Bpifrance Investissement

## Investors

- Karista (https://capitalatlas.ai/funds/karista) — Series A, Series B
- Boehringer Ingelheim Venture (https://capitalatlas.ai/funds/boehringer-ingelheim-venture) — Series A, Series B
- Inserm Transfert Initiative (https://capitalatlas.ai/funds/inserm-transfert-initiative) — Series A, Series B
- Bpifrance Investissement (https://capitalatlas.ai/funds/bpifrance-investissement) — Series A, Series B
- Pontifax Venture Capital (https://capitalatlas.ai/funds/pontifax-venture-capital) — Series A, Series B
- GF Securities — Series B
- GF Investments (Hong Kong) (https://capitalatlas.ai/funds/gf-investments-hong-kong) — Series B
- Pureos Bioventures (https://capitalatlas.ai/funds/pureos-bioventures) — Series B
- Korea Investment Partners (https://capitalatlas.ai/funds/korea-investment-partners) — Series B